Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease

Table 3 Hepatic lipid composition, MDA, and alpha-tocopherol levels (mean ± SD, n = 6)

Parameters	MCDD	MCDD	MCDD	MCDD	MCDD	MCDD	MCDD	MCDD	P
	FL	Rosiglitazone	Metformin	M+R	Ezetimibe	Valsartan	R+M+V	R+M+V+E
Triglyceride (mol/g liver)	21.8 ± 1.0	9.9 ± 1.4	13.1 ± 1.4	7.9 ± 1.9	10.1 ± 1.5	9.9 ± 1.7	6.9 ± 1.2	7.9 ± 2.1	< 0.0001
% change	+1263	-54	-40	-64	-53	-54	-68	-64
Cholesterol (mol/g liver)	1.6 ± 0.2	1.6 ± 0.2	1.6 ± 0.1	1.2 ± 0.2	1.2 ± 0.4	1.9 ± 0.3	1.3 ± 0.3	1.1 ± 0.4
% change	+245	0	0	-27	-25	+19	-19	-31	< 0.003
MDA (mol/g liver)	2.01 ± 0.04	1.2 ± 0.1	0.7 ± 0.1	0.9 ± 0.01	1.1 ± 0.1	1.2 ± 0.2	0.8 ± 0.1	0.6 ± 0.1	< 0.001
% change	+235	-40	-65	-55	-45	-40	-60	-70
Tocopherol- α (mg/g liver)	0.07 ± 0.03	0.13 ± 0.04	0.2 ± 0.1	0.2 ± 0.04	0.34 ± 0.09	0.14 ± 0.02	0.19 ± 0.04	0.38 ± 0.8	< 0.001
% change	-77	+86	+186	+186	+386	+100	+171	+443
Tocopherol-α /MDA ratio	0.003	0.01	0.028	0.02	0.03	0.011	0.023	0.06	< 0.001
% change	-94	+233	+833	+566	+900	+266	+666	+1900